A new look at established therapies: Practical tools for optimizing insulin use

Diabetes Educator

Volumn 36, Issue SUPPL. 2, 2010, Pages

  Gavin, James R ^a   Peragallo Dittko, Virginia ^b   Rodgers, Philip T ^c   Davis, Roslyn ^d  

^a EMORY UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ALGORITHM; ARTICLE; DIABETES MELLITUS; HUMAN; PATIENT EDUCATION; REPRODUCIBILITY;

ALGORITHMS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PATIENT EDUCATION AS TOPIC; REPRODUCIBILITY OF RESULTS; SULFONYLUREA COMPOUNDS;

EID: 77953759570     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721710369637     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. Number of People With Diabetes Increases to 24 Million. Atlanta, GA: Centers for Disease Control and Prevention, US Dept of Health and Human Services; 2008.
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta, GA: Centers for Disease Control and Prevention. US Department of Health and Human Services; 2005.
3. National Institute of Diabetes and Digestive and Kidney Disease. Diabetes Dateline Spring/Summer 2009: New Survey Results Show Huge Burden of Diabetes. http://diabetes.niddk.nih.gov/about/dateline/spr09/1.htm. Accessed November 16, 2009.
4. Saydah SH, Fradkin J., Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
5. Ramlo-Halsted BA, Edelman SV The natural history of type 2 diabetes. Implications for clinical practice. Prim Care. 1999;26:771-789.
6. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
7. Nathan DM, Buse JB, Davidson MB,et al.Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31:173-175.
8. Peragallo-Dittko V. Removing barriers to insulin therapy. Diabetes Educ. 2007;33:60S-65S.
9. Nathan DM, Buse JB, Davidson MB,et al.Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
10. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31:1927-1932.
11. Kruszynska YT, Home PD, Hanning I., Alberti KG Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia. 1987;30:16-21.
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
13. Weng J., Li Y., Xu W.,et al.Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008; 371:1753-1760.
14. Holman RR, Farmer AJ, Davies MJ,et al.Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736-1747.
15. Seipke G., Geisen K., Neubauer HP, Pittius C., Rogkamp R., Schwabe D. New insulin preparations with prolonged action profiles: A21-modified arginine insulins. Diabetologia. 1992;35:A4.
16. Hilgenfeld R., Durschug M., Geisen K.,et al.Controlling insulin bioavailability by crystal contact engineering. Diabetologia. 1992;35:A193.
17. Levemir [package insert]. Princeton, NJ: Novo Nordisk; 2005.
18. LANTUS (insulin glargine). Physicians' Desk Reference. 64th ed. Montvale, NJ: PDR Network, LLC; 2010:2996-3005.
19. Lantus [package insert]. Bridgewater, NJ: sanofi-aventis US, LLC; 2007.
20. Clinical Pharmacology. Web site. http://www.clinicalpharmacology.com/. Accessed June 17, 2009.
21. DeWitt DE, Hirsch IB Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289: 2254-2264.
22. Nathan DM Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349.
23. Monnier L., Colette C., Dunseath GJ, Owens DR The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30: 263-269.
24. Hirsch IB A real-world approach to insulin therapy in primary care practice. Clinical Diabetes. 2005;23:78-86.
25. Hirsch IB, Vega CP Optimal initiation of insulin in type 2 diabetes. MedGenMed. 2005;7:49.
26. Boehm BO, Home PD, Behrend C., Kamp NM, Lindholm A. Premixed insulin aspart 30 versus premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19:393-399.
27. Kilo C., Mezitis N., Jain R., Mersey J., McGill J., Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17:307-313.
28. Roach P., Yue L., Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care. 1999;22:1258-1261.
29. Malone JK, Bai S., Campaigne BN, Reviriego J., Augendre-Ferrante B. Twice-daily premixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005;22:374-381.
30. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034-2044.
31. Raskin P., Allen E., Hollander P.,et al.Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
32. Ligthelm RJ, Mouritzen U., Lynggaard H.,et al.Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006;114:511-519.
33. Peyrot M., Rubin RR, Lauritzen T.,et al.Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-2679.
34. Polonsky WH, Fisher L., Guzman S., Villa-Caballero L., Edelman SV Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28: 2543-2545.
35. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30:2478-2483.
36. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15:205-218.
37. Watts NB, Spanheimer RG, DiGirolamo M.,et al.Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1990;150:803-806.
38. Welch S. 10-10-10: 10 Minutes, 10 Months, 10 Years: A Life-Transforming Idea. 1st ed. New York, NY: Scribner; 2009.